On May 2022, on the basis of the results of this trial, the FDA approved a supplemental application for Ivosidenib, extending the indication in patients with newly diagnosed IDH1-mutated AML patients in older adults or those with comorbidities to include the combination with azacitidine [28]. This evidence concerns the gene IDH1 and acute myeloid leukemia.